Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic

ROSIE SCUCCIMARRI, EVELYN SUTTON and MARY-ANN FITZCHARLES
The Journal of Rheumatology June 2020, 47 (6) 783-786; DOI: https://doi.org/10.3899/jrheum.200369
ROSIE SCUCCIMARRI
Division of Pediatric Rheumatology, McGill University Health Centre, Montreal, Quebec, and Chair, Canadian Rheumatology Association (CRA) Therapeutics Committee;
MD
Roles: Associate Professor of Pediatrics
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EVELYN SUTTON
Division of Rheumatology, Dalhousie University, Halifax, Nova Scotia, and President, CRA;
MD
Roles: Professor of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARY-ANN FITZCHARLES
Alan Edwards Pain Management Unit, Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada, and Past Chair, CRA Therapeutics Committee.
MB, ChB
Roles: Associate Professor of Medicine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mfitzcharles@sympatico.ca
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past 70 years1. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of the coronavirus (SARS-CoV2)–associated disease called COVID-192,3. In this unprecedented time of a world viral pandemic that is associated with considerable mortality, rheumatologists can anticipate challenges in clinical care. We must counsel patients about the appropriate use of HCQ (CQ is not currently available in Canada) in the management of rheumatic diseases, provide valid scientific information regarding the current evidence for effect in COVID-19 disease, and be poised to provide alternative drug treatment in the event that HCQ may be allocated away from routine rheumatology clinical care to treat seriously ill viral-infected patients. These issues are pertinent and imminent for the rheumatologist and require an understanding of the current available knowledge, and consideration of a possible ethical dilemma in the event that drug supply is limited.

History of Antimalarial Therapy

Antimalarial therapy began in the mid-17th century with observations by Jesuit missionaries in Peru that the bark of a specific tree, later named Cinchona, could be used to treat the severe febrile illness now know to be malaria4. In the late 17th century, the Peruvian bark, mixed with rose leaves, lemon juice, and wine was a widely used secret treatment for fever in the malarial regions of England4. Quinine is a complex structured alkaloid and the active therapeutic component of the Cinchona tree. It was isolated and named in 1820 by 2 French chemists, Pelletier and Caventou4. Until the 1850s all the Cinchona bark came from the wild forests of the Andean republics of South America, leading to world market competition. Having secretly acquired seeds and saplings from South America, botanists from Kew Gardens worked with botanical gardens in India and Java to develop hybrid species of the Cinchona tree for plantations in Java, which became the main source of quinine4. Following World War I, when German troops were unable to access quinine from Java, German chemists produced a synthetic version of quinine in the early 1930s named mepacrine4. Mepacrine was subsequently also produced in the United States. Enemy propaganda during World War II spread the message that mepacrine would cause yellow skin discoloration as well as infertility, resulting in mass discontinuation of malaria prophylaxis by US troops in the Far East4. In an effort to stem the tide of malaria infections in US troops, US chemists synthesized CQ, a chemical variant of sontoquine, another synthetic antimalarial produced in Germany4.

Antimalarials as a Rheumatic Disease Treatment

During World War II, there were serendipitous observations of improved autoimmune skin disease and arthritis associated with CQ use5. Toxicity related to CQ was reduced when HCQ was developed by the addition of a β-hydroxy chain to the CQ molecule6. By the 1950s, reports were emerging of the clinical use of CQ and HCQ in the management of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)7,8,9. One such report in 1957 was by a Vancouver physician, Dr. Arthur W. Bagnall, who reported on a 4-year study of the use of CQ in 125 patients with RA who were “carefully followed up personally”8. With positive results in 70% of patients, Dr. Bagnall reported on the absence of “definite serious toxic effects” but did concede that there were minor toxic reactions. He also stated that there was a latent period of up to 3 months before effect, with maximum benefit for some delayed for as long as 6–12 months, leading to the statement that short duration treatment was of no value8.

Thereafter, both CQ and HCQ were identified as disease-modifying antirheumatic drugs (DMARD), with use continuing into the 21st century. With the emergence of additional synthetic DMARD, and in recent times biological DMARD, there has likely been a reduction in use of HCQ for patients with RA in particular; but HCQ remains a mainstay of treatment for an array of rheumatic autoimmune diseases, with the most important use in SLE10,11. In a first discontinuation study, the Canadian Hydroxychloroquine Study Group, led by Dr. John Esdaile, demonstrated that stopping HCQ in patients with stable SLE resulted in over twice the risk of having a disease flare12. This small pivotal study of 47 patients with stable SLE has promoted the current treatment practice, supported by guidelines worldwide, to maintain patients with SLE on HCQ indefinitely, even if disease severity requires introduction of more vigorous immunosuppressive treatments13,14,15. HCQ has proved invaluable in the management of skin manifestations of SLE as well as other immunological-related skin disorders16. There are more wide-reaching effects of HCQ with a recent study reporting attenuation of polyautoimmunity in patients with SLE17. In a nationwide Spanish study of 3679 SLE patients with 13.6% having polyautoimmunity (comorbid autoimmune thyroiditis, RA, scleroderma, inflammatory myopathy, and mixed connective tissue disease), antimalarial drugs were associated with a lower risk of polyautoimmunity (OR 0.50, 95% CI 0.38–0.67)17. An important advantage of HCQ is safety in pregnancy, first reported by Buchanan and colleagues in the United Kingdom in 199218. In a study of 100 pregnancies in patients with SLE, specifically addressing fetal loss related to circulating antiphospholipid antibodies, no fetal malformations were associated with HCQ use18. With 3 decades of study and clinical experience, HCQ has become one of the mainstays in controlling numerous immune conditions in pregnancy without fetal risk19,20.

Mechanism of Action and Recent Studies of CQ and HCQ in COVID-19

CQ and HCQ have in vitro potential to reduce activity of SARS-CoV-22. They are weak bases that accumulate preferentially in the acidic environment of lysosomes and phagolysosomes with the ability to block virus infectivity by raising endosomal pH, causing interference with virus/cell fusion and also interfering with glycosylation of cellular receptors of SARS-CoV. Therefore, CQ and HCQ function at both the viral entry and post-entry stages of infection2,3.

Given these in vitro effects, a number of clinical trials were rapidly initiated in China to test the efficacy and safety of CQ in COVID-19–associated pneumonia. Gao and colleagues have reported early preliminary findings on more than 100 patients that CQ was superior to placebo in reducing pneumonia exacerbation, duration of illness, and duration of clearance of virus21. This report must be viewed as extremely preliminary with minimal information regarding methodology and analysis of data provided. Even so, with these early results, the National Health Commission of the People’s Republic of China has included CQ in recommendations regarding management of COVID-19 pneumonia22. Colson and colleagues have suggested that HCQ, which has a similar mechanism of action as CQ, could be equally effective with a suggested dosage of 600 mg/day to reach serum concentrations of 1 μg/ml2,23. These researchers published a small nonrandomized study of 36 of 42 hospitalized patients who met inclusion criteria. Twenty-six received active treatment with a total 600 mg/day of HCQ for 10 days. Six of these 26 also received azithromycin (500 mg for 1 day, then 250 mg/day for 4 days) to prevent bacterial superinfection. Sixteen control patients did not receive these active treatments. Six of the HCQ patients discontinued treatment early: 3 patients were transferred to the intensive care unit (ICU), one died on Day 3, one was lost to followup, and another stopped because of nausea. No control patients were lost to followup. On Day 6, of the 20 remaining treated patients, 100% of HCQ/azithromycin, 57.1% HCQ only, and 12.5% of the control group showed nasopharyngeal clearance of the virus24. There are considerable limitations to this study: (1) the sample size was small; (2) the control group was recruited from other centers; (3) deaths (1 patient) and ICU admissions (3 patients) occurred early in the treatment group, and there were no clinical outcomes reported for the control group; and (4) treatment was not consistent for the active group24.

Ethical Questions in the Care of Rheumatology Patients

In this rapidly evolving health context, rheumatologists find themselves placed as the most common prescribers of an “old” drug that may have potential to be a lifesaver in this catastrophic era of a viral pandemic. Although in vitro studies of antimalarials and SARS-CoV2 are promising and have a mechanistic explanation, the clinical evidence at this time is lacking and must be seen as anecdotal. Rheumatologists are not the gatekeepers for access to HCQ, but some ethical issues require consideration. It is paramount that continued clinical care of patients with chronic diseases such as SLE and inflammatory arthritis who require HCQ maintenance treatment must proceed. Discontinuation of HCQ could lead to disease flare with significant morbidity and even mortality in patients with SLE. The safety of pregnant patients with rheumatic diseases requiring treatment with HCQ must be strongly protected.

Anticipating limited availability of HCQ in the coming weeks and months, the question will be, “who should get HCQ treatment?” Rheumatologists must advocate strongly for continued access to HCQ for valid clinical indications. In addition to SLE, there are many patients with various autoimmune rheumatic diseases including palindromic rheumatism, Sjögren syndrome, cutaneous SLE, and even milder forms of RA that currently have their disease sufficiently controlled with HCQ, not requiring treatment with more complex DMARD; they should not be denied continued treatment. Other conditions such as osteoarthritis are not indications for use of HCQ and it should not be prescribed25. Rheumatologists must join the scientific community and support the recommendation that any use of HCQ to treat COVID-19 must be limited to the hospital and/or ICU settings within the context of a formal research protocol. Therefore, off-label use outside these settings should be prohibited. Because there is no current evidence that HCQ can prevent SARS-CoV2 infection, the public should be informed not to self-medicate by requesting a prescription or “borrowing” from a family member for whom it is prescribed legitimately. Importantly, patients should be educated never to share their medication. With judicious use, we hope that all those with diseases that require HCQ will continue to have access to it, and we urge producers and suppliers to be proactive in ensuring sufficient supply.

Despite these strategies, and in the event of a limited supply of HCQ, rheumatologists may have to choose which of their patients should continue taking HCQ. This ethical decision will be difficult if rheumatologists are forced to avoid prescribing HCQ. Rheumatic disease patients with life-threatening illnesses such as SLE, or pregnant patients, must have priority to continue treatment. We will need to determine for which patients with inflammatory arthritis HCQ is less essential. This may particularly apply to those whose disease is well controlled and may currently be receiving an additional DMARD. Empathetic discussion with a patient in this setting could be framed in the context of a societal contribution toward an overwhelming health disaster, with opportunity to have some influence on outcome for others. Whether this step could truly influence access and supply of HCQ as a potential treatment for this current human catastrophe is unknown. In this unprecedented time, every single effort should be made toward stemming this most awful global event, but with caution to respect and adhere to the tenets of evidence-based medicine.

REFERENCES

  1. 1.↵
    1. Schrezenmeier E,
    2. Dorner T
    . Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 2020;16:155–66.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Colson P,
    2. Rolain JM,
    3. Lagier JC,
    4. Brouqui P,
    5. Raoult D
    . Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020 Mar 4 (E-pub ahead of print).
  3. 3.↵
    1. Wang M,
    2. Cao R,
    3. Zhang L,
    4. Yang X,
    5. Liu J,
    6. Xu M,
    7. et al.
    Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269–71.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Butler AR,
    2. Khan S,
    3. Ferguson E
    . A brief history of malaria chemotherapy. J R Coll Physicians Edinb 2010;40:172–7.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Shukla AM,
    2. Wagle Shukla A
    . Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. Drugs Context 2019;8:2019-9-1.
  6. 6.↵
    1. Wallace DJ
    . The history of antimalarials. Lupus 1996;5 Suppl 1:S2–3.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Mullins JF,
    2. Watts FL,
    3. Wilson CJ
    . Plaquenil in the treatment of lupus erythematosus. J Am Med Assoc 1956;161:879–81.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Bagnall AW
    . The value of chloroquine in rheumatoid disease: a four-year study of continuous therapy. Can Med Assoc J 1957;77:182–94.
    OpenUrlPubMed
  9. 9.↵
    1. Hamilton EB,
    2. Scott JT
    . Hydroxychloroquine sulfate (“plaguenil”) in treatment of rheumatoid arthritis. Arthritis Rheum 1962;5:502–12.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Scherbel AL
    . Use of synthetic antimalarial drugs and other agents for rheumatoid arthritis: historic and therapeutic perspectives. Am J Med 1983;75:1–4.
    OpenUrlPubMed
  11. 11.↵
    1. Lever E,
    2. Alves MR,
    3. Isenberg DA
    . Towards precision medicine in systemic lupus erythematosus. Pharmgenomics Pers Med 2020;13:39–49.
    OpenUrl
  12. 12.↵
    1. Canadian Hydroxychloroquine Study Group
    . A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150–4.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Fanouriakis A,
    2. Kostopoulou M,
    3. Alunno A,
    4. Aringer M,
    5. Bajema I,
    6. Boletis JN,
    7. et al.
    2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 2019;78:736–45.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Hahn BH,
    2. McMahon MA,
    3. Wilkinson A,
    4. Wallace WD,
    5. Daikh DI,
    6. Fitzgerald JD,
    7. et al;
    8. American College of Rheumatology
    . American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012;64:797–808.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Aouhab Z,
    2. Hong H,
    3. Felicelli C,
    4. Tarplin S,
    5. Ostrowski RA
    . Outcomes of systemic lupus erythematosus in patients who discontinue hydroxychloroquine. ACR Open Rheumatol 2019;1:593–9.
    OpenUrl
  16. 16.↵
    1. Shi H,
    2. Gudjonsson JE,
    3. Kahlenberg JM
    . Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol 2020;32:208–14.
    OpenUrl
  17. 17.↵
    1. Mena-Vázquez N,
    2. Fernández-Nebro A,
    3. Pego-Reigosa JM,
    4. Galindo M,
    5. Melissa-Anzola A,
    6. Uriarte-Isacelay E,
    7. et al.
    Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. Rheumatology 2019 Dec 6 (E-pub ahead of print).
  18. 18.↵
    1. Buchanan NM,
    2. Khamashta MA,
    3. Morton KE,
    4. Kerslake S,
    5. Baguley EA,
    6. Hughes GR
    . A study of 100 high risk lupus pregnancies. Am J Reprod Immunol 1992;28:192–4.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Gerosa M,
    2. Schioppo T,
    3. Meroni PL
    . Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opin Pharmacother 2016;17:1539–47.
    OpenUrl
  20. 20.↵
    1. Abarientos C,
    2. Sperber K,
    3. Shapiro DL,
    4. Aronow WS,
    5. Chao CP,
    6. Ash JY
    . Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. Expert Opin Drug Saf 2011;10:705–14.
    OpenUrlPubMed
  21. 21.↵
    1. Gao J,
    2. Tian Z,
    3. Yang X
    . Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72–3.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. [Article in Chinese] Zhonghua Jie He He Hu Xi Za Zhi 2020;43:185–8.
    OpenUrl
  23. 23.↵
    1. Lagier JC,
    2. Fenollar F,
    3. Lepidi H,
    4. Giorgi R,
    5. Million M,
    6. Raoult D
    . Treatment of classic Whipple’s disease: from in vitro results to clinical outcome. J Antimicrob Chemother 2014;69:219–27.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Gautret P,
    2. Lagier JC,
    3. Parola P,
    4. Hoang VT,
    5. Meddeb L,
    6. Mailhe M,
    7. et al.
    Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020:105949.
  25. 25.↵
    1. Ghouri A,
    2. Conaghan PG
    . Treating osteoarthritis pain: recent approaches using pharmacological therapies. Clin Exp Rheumatol 2019;37 Suppl 120:124–9.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 47, Issue 6
1 Jun 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic
ROSIE SCUCCIMARRI, EVELYN SUTTON, MARY-ANN FITZCHARLES
The Journal of Rheumatology Jun 2020, 47 (6) 783-786; DOI: 10.3899/jrheum.200369

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic
ROSIE SCUCCIMARRI, EVELYN SUTTON, MARY-ANN FITZCHARLES
The Journal of Rheumatology Jun 2020, 47 (6) 783-786; DOI: 10.3899/jrheum.200369
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • History of Antimalarial Therapy
    • Antimalarials as a Rheumatic Disease Treatment
    • Mechanism of Action and Recent Studies of CQ and HCQ in COVID-19
    • Ethical Questions in the Care of Rheumatology Patients
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • More Evidence on the Validity of the Measurement Properties of PROMIS Computerized Adaptive Tests in Systemic Lupus Erythematosus
  • A Move Toward Precision: Innovations in Measuring Spinal Mobility in Axial Spondyloarthritis
  • Chew on This: The Afterbite of Temporomandibular Joint Involvement in Adults With Juvenile Idiopathic Arthritis
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2023 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire